Eli Lilly and Co to Provide Alzheimer's Disease Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the 2023 AAIC Lilly Alzheimer's Disease Update Conference Call.(Operator Instructions)
I would now like to turn the conference over to your host, Lauren Zierke, Executive Director of Investor Relations. Please go ahead.
Thanks, Tom. Good evening from the Alzheimer's Association International Conference in Amsterdam. Thank you for joining us for Eli Lilly and Company's 2023 Alzheimer's Disease Update. I'm Lauren Zierke, Executive Director, Investor Relations.
Joining me on today's call are Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Anne White, President of Lilly Neuroscience; Dr. Mark Mintun, Group Vice President of Neuroscience Research and Development, President of Avid Radio Pharmaceuticals; and Dr. John Sims, Head of Clinical Development for donanemab.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |